Iduronate 2-sulfatase (IDS) Drug Discovery Landscape & Assay Solutions
- By admin
- 12 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucopolysaccharidosis Type II (MPS II) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IDS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IDS Recombinant Enzyme (Wild-Type & Pathogenic Mutant Panel). High purity (>95%), endotoxin <1 EU/μg, sequence verified. HEK293/CHO expressed preserving native glycosylation for uptake studies. | View IDS Products |
| Gene Delivery | IDS Lentivirus/ORF Premade Particles. Full-length ORF for stable MPS II cellular model generation and gene therapy potency assays. | View IDS Products |
| Benchmark Ab | Anti-IDS Recombinant Antibody (including Pabinafusp alfa biosimilar sequence). High-affinity detection antibody for PK/ADA assay development. | View IDS Products |
| Validator | IDS siRNA Set. For specific knockdown verification in cellular deficiency models (MPS II). | View IDS Products |
| Related Target: TfR1 (Transferrin Receptor 1) | TFRC ECD-Fc Fusion. For BBB-penetrating ERT fusion validation (Pabinafusp mechanism). | View TFRC Products |
| Related Target: CI-MPR/IGF2R | Cation-Independent Mannose-6-Phosphate Receptor (ECD). For uptake mechanism binding studies (M6PR-dependent internalization). | View IGF2R Products |
| Related Target: SGSH | Heparan sulfate degradation pathway enzyme (MPS IIIA); synergistic LSD target for combination therapy research. | View SGSH Products |
| Related Target: GUSB | Beta-glucuronidase (MPS VII); parallel lysosomal enzyme replacement modality. | View GUSB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Standardization (4-MU substrate) | High-purity IDS (>95%) with defined theoretical specific activity; low endotoxin for in vivo ERT modeling. |
| Lysosomal Uptake & M6P-dependent Internalization | HEK293-expressed proteins preserving native glycosylation and mannose-6-phosphate modifications; suitable for CI-MPR binding and cellular uptake assays. |
| Blood-Brain Barrier Penetration (Next-gen ERT) | Anti-TfR1 fusion validation reagents available (TfR1 ECD + IDS antigen dual-binding assays). |
| Immunogenicity (ADA) Screening | Anti-IDS benchmark antibody reference standards included; null-mutant protein controls for assay calibration. |
| Cross-species PK/Tox Evaluation | Human/Mouse/Cyno IDS ortholog proteins available with >95% purity for preclinical safety studies. |
| Assay Specificity vs. Other Sulfatases | Sequence-verified proteins; validated siRNA for target-specific knockdown confirmation to avoid cross-reactivity. |
Live IDS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Hunter syndrome)
- ➤ Latest BBB Crossing Research
- ➤ Latest Resistance & Immunogenicity Research
- ➤ Recent Patent Filings (BBB Penetration)
Global Clinical Landscape & Future Outlook
The IDS therapeutic landscape is transitioning from standard intravenous ERT (idursulfase, Elaprase) to next-generation Blood-Brain Barrier (BBB) penetrating enzyme replacement therapies and potential one-time gene therapy solutions. As the field addresses the critical unmet need for CNS symptom treatment, robust assays for BBB penetration (e.g., TfR1-mediated transcytosis), neuronal uptake efficiency, and immunogenicity are becoming primary differentiators for next-in-class candidates. First-generation therapies stabilize somatic symptoms but fail to address neurocognitive decline, driving R&D toward engineered delivery vehicles (ETV, AAV) and ex vivo gene therapy approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Standard ERT | Takeda (Elaprase), GC Pharma (Hunterase) | MPS II (Somatic) | Enzymatic activity & uptake assays using high-purity, properly glycosylated recombinant IDS. |
| BBB-Penetrating ERT | JCR Pharmaceuticals (Pabinafusp alfa), Denali Therapeutics (DNL310, ETV:IDS) | MPS II (CNS + Somatic) | Bifunctional binding assay (TfR1 + IDS dual specificity); transcytosis assay with high-purity TfR1 and IDS. |
| Gene Therapy (AAV) | Sarepta Therapeutics, Regenxbio (RGX-121), Sangamo | MPS II (CNS-targeted or systemic) | Potency assays (IDS expression quantification); transduction assay using lentiviral controls. |
| Ex Vivo HSPC Gene Therapy | Orchard Therapeutics (OTL-201) | MPS II (Systemic + CNS) | Cell engineering & enzyme secretion assay; lentiviral IDS ORF for stable transduction. |
| Biosimilar ERT | Emerging Developers | MPS II (Somatic) | Immunogenicity & activity comparability assays (mutant & WT panels). |